Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (Bad Cholesterol) and Triglycerides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~* Participants with hypercholesterolemia and hypertriglyceridemia.~* Participants had the following fasting lipid results following a greater than or equal to 12 hour fasting period (measured at the Screening Visit(s)):~  * Triglycerides level greater than or equal to 150 milligrams/deciliter (mg/dL) and less than 400 milligrams/deciliter, and~ * Low-density lipoprotein cholesterol greater than or equal to 160 milligrams/deciliter and less than or equal to 240 milligrams/deciliter.~Exclusion Criteria~* Participants with certain chronic or unstable medical conditions.~* Participants receiving coumarin anticoagulants, systemic cyclosporins, or certain other medications.~* Pregnant or lactating women, or women intending to become pregnant.~* Participants with diabetes mellitus that is poorly controlled.~* Participant was of Asian ancestry (having Filipino, Chinese, Japanese, Korean, Vietnamese, or Asian-Indian origin).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A - ABT-143 capsules 5/135 mg (Type: EXPERIMENTAL): ABT-143 capsules 5/135 mg - ABT-143 (rosuvastatin 5 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
- B - ABT-143 capsules 10/135 mg (Type: EXPERIMENTAL): ABT-143 capsules 10/135 mg - ABT-143 (rosuvastatin 10 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
- C - ABT-143 capsules 20/135 mg (Type: EXPERIMENTAL): ABT-143 capsules 20/135 mg - ABT-143 (rosuvastatin 20 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
- D - Simvastatin capsules 40 mg (Type: ACTIVE_COMPARATOR): Simvastatin capsules 40 mg daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).